Evaluation of asymmetric dimethylarginine, nitric oxide levels and associated independent variables in obese and lean patients with polycystic ovarian syndrome

Gynecological Endocrinology

Volumn 27, Issue 9, 2011, Pages 609-614

  Türkçüoǧlu, Ilgin ^a   Engin Üstün, Yaprak ^a   Turan, Fahri ^b   Kali, Zercan ^a   Bay Karabulut, Aysun ^b   Meydanli, Mutlu ^a   Kafkasli, Ayşe ^a  

^a Inöönü University   (Turkey)

^b Tnöönü University   (Turkey)

Author keywords

asymmetric dimethylarginine; cardiovascular; insulin resistance; nitric oxide; obesity; PCOS

Indexed keywords

FOLLITROPIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LUTEINIZING HORMONE; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; PRASTERONE SULFATE; TESTOSTERONE; THYROTROPIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DIET RESTRICTION; ENDOTHELIAL DYSFUNCTION; FEMALE; FOLLITROPIN BLOOD LEVEL; HOMEOSTASIS MODEL OF INSULIN RESISTANCE; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LUTEINIZING HORMONE BLOOD LEVEL; MENSTRUAL CYCLE; METABOLIC PARAMETERS; OBESITY; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROSPECTIVE STUDY; TESTOSTERONE BLOOD LEVEL; THYROTROPIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL;

ADOLESCENT; ADULT; ARGININE; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; CHOLESTEROL; FEMALE; HORMONES; HUMANS; NITRIC OXIDE; OBESITY; POLYCYSTIC OVARY SYNDROME; RISK FACTORS; YOUNG ADULT;

EID: 80051478473     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590.2010.507291     Document Type: Article

References (47)

1. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004;89:2745-2749. (Pubitemid 38766360)
2. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 1998;83:3078-3082. (Pubitemid 28500937)
3. Balen AH, Conway GS, Kaltsas G, Techatrasak K, Manning PJ, West C, Jacob HS. Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients. Hum Reprod 1995;10:2107-2111.
4. Book CB, Dunaif A. Selective insulin resistance in the polycystic ovary syndrome. J Clin Endocrinol Metab 1999;84: 3110-3116. (Pubitemid 30646930)
5. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999;84:165-169. (Pubitemid 29036695)
6. Rizzo M, Berneis K, Hersberger M, Pepe I, Di Fede G, Rini GB, Spinas GA, Carmina E. Milder forms of atherogenic dyslipidemia in ovulatory versus anovulatory polycystic ovary syndrome phenotype. Hum Reprod 2009;24:2286-2292.
7. Holte J, Gennarelli G, Berne C, Bergh T, Lithell H. Elevated ambulatory day-time blood pressure in women with polycystic ovary syndrome: a sign of a pre-hypertensive state? Hum Reprod 1996;11:23-28. (Pubitemid 26047667)
8. Glueck CJ, Papanna R, Wang P, Goldenberg N, Sieve-Smith L. Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. Metabolism 2003;52:908-915. (Pubitemid 36957780)
9. Bhattacharya SM, Ghosh M. Insulin resistance and adolescent girls with polycystic ovary syndrome. J Pediatr Adolesc Gynecol 2010;23:158-161.
10. Napoli C, Ignarro LJ. Nitric oxide and atherosclerosis. Nitric Oxide 2001;5:88-97. (Pubitemid 34142732)
11. Schulze F, Lenzen H, Hanefeld C, Bartling A, Osterziel KJ, Goudeva L, Schmidt-Lucke C, Kusus M, Maas R, Schwedhelm E, et al. Asymmetric dimethylarginine is an independent risk factor for coronary heart disease: results from the multicenter Coronary Artery Risk Determination investigating the Influence of ADMA Concentration (CARDIAC) study. Am Heart J 2006;152:493 e1-493 e8.
12. Boger RH, Sydow K, Borlak J, Thum T, Lenzen H, Schubert B, Tsikas D, Bode-Boger SM. LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S- adenosylmethionine-dependent methyltransferases. Circ Res 2000;87:99-105. (Pubitemid 30616904)
13. Faraci FM, Brian JE Jr, Heistad DD. Response of cerebral blood vessels to an endogenous inhibitor of nitric oxide synthase. Am J Physiol 1995;269:H1522-H1527. (Pubitemid 3005958)
14. Achan V, Broadhead M, Malaki M, Whitley G, Leiper J, MacAllister R, Vallance P. Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol 2003;23:1455-1459. (Pubitemid 36994536)
15. Calver A, Collier J, Leone A, Moncada S, Vallance P. Effect of local intra-arterial asymmetric dimethylarginine (ADMA) on the forearm arteriolar bed of healthy volunteers. J Hum Hypertens 1993;7:193-194. (Pubitemid 23138200)
16. Ardigo D, Stuehlinger M, Franzini L, Valtuena S, Piatti PM, Pachinger O, Reaven GM, Zavaroni I. ADMA is independently related to flow-mediated vasodilation in subjects at low cardiovascular risk. Eur J Clin Invest 2007;37:263-269. (Pubitemid 46439414)
17. Boger RH, Lentz SR, Bode-Boger SM, Knapp HR, Haynes WG. Elevation of asymmetrical dimethylarginine may mediate endothelial dysfunction during experimental hyperhomocyst( e)inaemia in humans. Clin Sci (Lond) 2001;100:161-167. (Pubitemid 32165360)
18. Dayal S, Lentz SR. ADMA and hyperhomocysteinemia. Vasc Med 2005;10 (Suppl 1):S27-S33. (Pubitemid 43137265)
19. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992;339:572-575.
20. Cavusoglu E, Ruwende C, Chopra V, Poludasu S, Yanamadala S, Frishman WH, Eng C, Pinsky DJ, Marmur JD. Relation of baseline plasma ADMA levels to cardiovascular morbidity and mortality at two years in men with diabetes mellitus referred for coronary angiography. Atherosclerosis 2010;210:226-231.
21. Leong T, Zylberstein D, Graham I, Lissner L, Ward D, Fogarty J, Bengtsson C, Bjorkelund C, Thelle D. Asymmetric dimethylarginine independently predicts fatal and nonfatal myocardial infarction and stroke in women: 24-year follow-upof the population study of women in Gothenburg. Arterioscler Thromb Vasc Biol 2008;28:961-967. (Pubitemid 351544114)
22. Boger RH, Sullivan LM, Schwedhelm E, Wang TJ, Maas R, Benjamin EJ, Schulze F, Xanthakis V, Benndorf RA, Vasan RS, Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community. Circulation 2009;119:1592-1600.
23. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19-25.
24. Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS, Tannenbaum SR. Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids. Anal Biochem 1982;126:131-138. (Pubitemid 13203451)
25. Faloia E, Canibus P, Gatti C, Frezza F, Santangelo M, Garrapa GG, Boscaro M. Body composition, fat distribution and metabolic characteristics in lean and obese women with polycystic ovary syndrome. J Endocrinol Invest 2004;27:429.
26. Elting MW, Korsen TJ, Schoemaker J. Obesity, rather than menstrual cycle pattern or follicle cohort size, determines hyperinsulinaemia, dyslipidaemia and hypertension in ageing women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2001;55:767-776. (Pubitemid 34008748)
27. Glueck CJ, Morrison JA, Friedman LA, Goldenberg N, Stroop DM, Wang P. Obesity, free testosterone, and cardiovascular risk factors in adolescents with polycystic ovary syndrome and regularly cycling adolescents. Metabolism 2006;55:508-514.
28. Charitidou C, Farmakiotis D, Zournatzi V, Pidonia I, Pegiou T, Karamanis N, Hatzistilianou M, Katsikis I, Panidis D. The administration of estrogens, combined with anti-androgens, has beneficial effects on the hormonal features and asymmetric dimethyl-arginine levels, in women with the polycystic ovary syndrome. Atherosclerosis 2008;196:958-965.
29. Ozgurtas T, Oktenli C, Dede M, Tapan S, Kenar L, Sanisoglu SY, Yesilova Z, YenenMC, ErbilMK, Baser IY. Metformin and oral contraceptive treatments reduced circulating asymmetric dimethylarginine (ADMA) levels in patients with polycystic ovary syndrome (PCOS). Atherosclerosis 2008;200: 336-344.
30. Heutling D, Schulz H, Nickel I, Kleinstein J, Kaltwasser P, Westphal S, Mittermayer F, Wolzt M, Krzyzanowska K, Randeva H, et al. Asymmetrical dimethylarginine, inflammatory and metabolic parameters in women with polycystic ovary syndrome before and after metformin treatment. J Clin Endocrinol Metab 2008;93:82-90.
31. Moran LJ, Hutchison SK, Meyer C, Zoungas S, Teede HJ. A comprehensive assessment of endothelial function in overweight women with and without polycystic ovary syndrome. Clin Sci (Lond) 2009;116:761-770.
32. Rajendran S, Willoughby SR, Chan WP, Liberts EA, Heresztyn T, Saha M, Marber MS, Norman RJ, Horowitz JD. Polycystic ovary syndrome is associated with severe platelet and endothelial dysfunction in both obese and lean subjects. Atherosclerosis 2009;204:509-514.
33. Demirel F, Bideci A, Cinaz P, Camurdan MO, Biberoglu G, Yesilkaya E, Hasanoglu A. Serum leptin, oxidized low density lipoprotein and plasma asymmetric dimethylarginine levels and their relationship with dyslipidaemia in adolescent girls with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2007;67:129-134. (Pubitemid 46955452)
34. Pamuk BO, Torun AN, KulaksizogluM, Ertugrul D, Ciftci O, Kulaksizoglu S, Yildirim E, Demirag NG. Asymmetric dimethylarginine levels and carotid intima-media thickness in obese patients with polycystic ovary syndrome and their relationship to metabolic parameters. Fertil Steril 2010;93:1227-1233.
35. Kaya C, Pabuccu R, Koca C, Oguz AK, Erkan AF, Korkmaz A, Erbas D. Relationship between interleukin-6 levels and ambulatory blood pressure in women with polycystic ovary syndrome. Fertil Steril, in press.
36. Karadeniz M, Erdogan M, Tamsel S, Zengi A, Alper GE, Caglayan O, Saygili F, Yilmaz C. Oxidative stress markers in young patients with polycystic ovary syndrome, the relationship between insulin resistances. Exp Clin Endocrinol Diabetes 2008;116:231-235. (Pubitemid 351600585)
37. Nacul AP, Andrade CD, Schwarz P, de Bittencourt PI Jr, Spritzer PM. Nitric oxide and fibrinogen in polycystic ovary syndrome: associations with insulin resistance and obesity. Eur J Obstet Gynecol Reprod Biol 2007;133:191-196. (Pubitemid 47069681)
38. Walch K, Kolbus A, Hefler-Frischmuth K. Polymorphisms of the endothelial nitric oxide synthase gene in premenopausal women with polycystic ovary syndrome. Maturitas 2008;61: 256-259.
39. Palm F, Onozato ML, Luo Z, Wilcox CS. Dimethylarginine dimethylaminohydrolase (DDAH): expression, regulation, and function in the cardiovascular and renal systems. Am J Physiol Heart Circ Physiol 2007;293:H3227-H3245. (Pubitemid 350230862)
40. Ito A, Tsao PS, Adimoolam S, Kimoto M, Ogawa T, Cooke JP. Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 1999;99:3092-3095. (Pubitemid 29289071)
41. Stuhlinger MC, Tsao PS, Her JH, Kimoto M, Balint RF, Cooke JP. Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine. Circulation 2001;104:2569-2575. (Pubitemid 33104795)
42. Zhang WZ, Venardos K, Chin-Dusting J, Kaye DM. Adverse effects of cigarette smoke on NO bioavailability: role of arginine metabolism and oxidative stress. Hypertension 2006;48:278-285. (Pubitemid 44309824)
43. Wijeyaratne CN, Nirantharakumar K, Balen AH, Barth JH, Sheriff R, Belchetz PE. Plasma homocysteine in polycystic ovary syndrome: does it correlate with insulin resistance and ethnicity? Clin Endocrinol (Oxf) 2004;60:560-567. (Pubitemid 38669845)
44. Schachter M, Raziel A, Friedler S, Strassburger D, Bern O,Ron-El R. Insulin resistance in patients with polycystic ovary syndrome is associated with elevated plasma homocysteine. Hum Reprod 2003;18:721-727. (Pubitemid 36426948)
45. Macut D, Damjanovic S, Panidis D, Spanos N, Glisic B, Petakov M, Rousso D, Kourtis A, Bjekic J, Milic N. Oxidised low-density lipoprotein concentration - early marker of an altered lipid metabolism in young women with PCOS. Eur J Endocrinol 2006;155:131-136. (Pubitemid 44103381)
46. Carmina E, Chu MC, Longo RA, Rini GB, Lobo RA. Phenotypic variation in hyperandrogenic women influences the findings of abnormal metabolic and cardiovascular risk parameters. J Clin Endocrinol Metab 2005;90:2545-2549. (Pubitemid 40686289)
47. Welt CK, Gudmundsson JA, Arason G, Adams J, Palsdottir H, Gudlaugsdottir G, Ingadottir G, Crowley WF. Characterizing discrete subsets of polycystic ovary syndrome as defined by the Rotterdam criteria: the impact of weight on phenotype and metabolic features. J Clin Endocrinol Metab 2006;91: 4842-4848. (Pubitemid 44917316)